Home LiteratureArticle Details
PMID: 7996299 Published · ppublish English Journal Article Review

Clostridium difficile infection: a common clinical problem for the general internist.

Journal of general internal medicine ·Vol. 9 ·No. 9 ·1994-09-00 ·Pages 528-33

Caputo GM, Weitekamp MR, Bacon AE, Whitener C

Abstract

Considering the current wide use of antimicrobial agents, the general internist is commonly faced with the patient at risk for diarrhea due to C. difficile. The diagnosis should be considered for any patient with diarrhea who has received any type of antibiotic therapy in the preceding 4-6 weeks. Symptoms may range from a minor bout of diarrhea to fulminant and fatal colitis. Diagnosis usually requires demonstration of the toxin in stool; culture of the organism and fiberoptic endoscopy may play an adjunctive role in selected clinical settings. The ultimate goal in the treatment for C. difficile infection is to repopulate the normal colonic flora in the most efficacious manner. Minimally symptomatic patients may respond to discontinuing the offending antimicrobial agent or using nonspecific binding agents. Oral vancomycin continues to be the "gold standard" for specific treatment, while metronidazole therapy is considered the first-line agent for individuals with milder infection. Oral bacitracin shows promise, though large studies are lacking. Patients with multiple relapses of C. difficile diarrhea can be treated with prolonged courses of vancomycin or a combination of vancomycin and rifampin. Intensive care unit patients who are NPO have few therapeutic options besides intravenous administration of metronidazole and oral administration of vancomycin via clamped nasogastric tube. Preventive efforts are directed at cautious use of antibiotics and the use of vinyl gloves when caring for patients with known infection.

MeSH Terms
Clostridioides difficile Diarrhea/microbiology Enterocolitis, Pseudomembranous/diagnosis,prevention & control,therapy Enterotoxins Family Practice Humans Metronidazole/therapeutic use Vancomycin/therapeutic use
Chemicals
Enterotoxins Metronidazole Vancomycin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Caputo G M
Department of Medicine, Pennsylvania State University College of Medicine, Milton S. Hershey Medical Center, Hershey 17033-2390.
Weitekamp M R
Bacon A E
Whitener C
References (65)
65 references, click to expand
  1. Clostridium difficile in a pediatric outpatient population.
    Pediatr Infect Dis. 1982 Sep-Oct;1(5):336-8 PMID: 7155966
  2. Clindamycin-associated colitis. A prospective study.
    Ann Intern Med. 1974 Oct;81(4):429-33 PMID: 4412460
  3. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.
    Gastroenterology. 1980 Mar;78(3):431-4 PMID: 7053190
  4. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.
    Eur J Clin Microbiol. 1987 Feb;6(1):51-3 PMID: 3569251
  5. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease.
    Gastroenterology. 1981 Apr;80(4):693-6 PMID: 7202941
  6. Treatment of antibiotic-associated enterocolitis with vancomycin.
    Rev Infect Dis. 1981 Nov-Dec;3 suppl:S273-81 PMID: 7342291
  7. In vitro synergy studies with Clostridium difficile.
    Antimicrob Agents Chemother. 1991 Mar;35(3):582-3 PMID: 2039211
  8. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission.
    Am J Med. 1990 Feb;88(2):137-40 PMID: 2301439
  9. Exacerbation of ulcerative colitis.
    Gastroenterology. 1991 Jul;101(1):254-62 PMID: 2044913
  10. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin.
    J Pediatr. 1991 Apr;118(4 Pt 1):633-7 PMID: 1901084
  11. Clostridium difficile cytotoxin in a pediatric population.
    Am J Dis Child. 1983 Mar;137(3):271-4 PMID: 6823926
  12. Pseudomembranous colitis following resection for Hirschsprung's disease.
    J Pediatr Surg. 1992 Oct;27(10):1261-4 PMID: 1403498
  13. Positive role of Clostridium difficile infection in diarrhea in infants and children.
    Am J Gastroenterol. 1991 Jun;86(6):685-9 PMID: 2038989
  14. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins.
    J Infect Dis. 1980 Jan;141(1):92-7 PMID: 7365273
  15. Failure of parenteral metronidazole in the treatment of pseudomembranous colitis.
    J Infect Dis. 1988 Nov;158(5):1146-7 PMID: 3183427
  16. Faecal toxin and severity of antibiotic-associated pseudomembranous colitis.
    J Clin Pathol. 1981 May;34(5):548-51 PMID: 7251895
  17. Failure of intravenous vancomycin and intravenous metronidazole to prevent or treat antibiotic-associated pseudomembranous colitis.
    J Infect Dis. 1989 Jun;159(6):1154-5 PMID: 2491408
  18. Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study.
    Gastroenterology. 1982 Dec;83(6):1259-60 PMID: 7129030
  19. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis.
    CMAJ. 1990 May 15;142(10):1049-51 PMID: 2186849
  20. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy.
    Gut. 1983 Mar;24(3):206-12 PMID: 6826104
  21. Clostridium difficile in the elderly.
    J Infect. 1991 May;22(3):310-2 PMID: 2071922
  22. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial.
    Arch Intern Med. 1986 Jun;146(6):1101-4 PMID: 3521518
  23. Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy.
    Am J Pediatr Hematol Oncol. 1992 Nov;14(4):361-4 PMID: 1456403
  24. Treatment of Clostridium difficile colitis.
    Gastroenterology. 1985 Nov;89(5):1192-5 PMID: 3899842
  25. Diagnosis and treatment of Clostridium difficile colitis.
    JAMA. 1993 Jan 6;269(1):71-5 PMID: 8416409
  26. Lack of relationship of Clostridium difficile to antibiotic-associated diarrhea in children.
    Pediatr Infect Dis. 1983 Sep-Oct;2(5):364-6 PMID: 6634465
  27. Nosocomial acquisition of Clostridium difficile infection.
    N Engl J Med. 1989 Jan 26;320(4):204-10 PMID: 2911306
  28. Pseudomembranous colitis: CT evaluation of 26 cases.
    Radiology. 1991 Jul;180(1):57-60 PMID: 2052723
  29. Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces.
    Rev Infect Dis. 1991 Nov-Dec;13(6):1053-60 PMID: 1775837
  30. Nosocomial Clostridium difficile colonisation and disease.
    Lancet. 1990 Jul 14;336(8707):97-100 PMID: 1975332
  31. Pseudomembranous colitis: a lethal complication of Hirschsprung's disease unrelated to antibiotic usage.
    J Pediatr Surg. 1987 Mar;22(3):257-9 PMID: 3559870
  32. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
    Antimicrob Agents Chemother. 1991 Jan;35(1):195-7 PMID: 1826593
  33. Clostridium difficile and gastroenteritis: how strong is the association in children?
    Pediatr Infect Dis. 1984 Jan-Feb;3(1):4-6 PMID: 6701103
  34. Antibiotic-associated diarrhea.
    Clin Infect Dis. 1992 Oct;15(4):573-81 PMID: 1420669
  35. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG.
    Lancet. 1987 Dec 26;2(8574):1519 PMID: 2892070
  36. Pseudomembranous colitis in children and adults.
    Br J Hosp Med. 1986 Jan;35(1):37-42 PMID: 3955286
  37. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile.
    Infection. 1984 Jul-Aug;12(4):276-9 PMID: 6490173
  38. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    J Antimicrob Chemother. 1990 Nov;26(5):627-33 PMID: 1688341
  39. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients.
    Lancet. 1989 May 27;1(8648):1156-60 PMID: 2566734
  40. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.
    Lancet. 1983 Nov 5;2(8358):1043-6 PMID: 6138597
  41. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.
    J Clin Gastroenterol. 1987 Apr;9(2):155-9 PMID: 3571889
  42. Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii.
    Dig Dis Sci. 1990 Jul;35(7):897-901 PMID: 2364845
  43. Clostridium difficile toxin in faecal specimens of healthy children and children with diarrhoea.
    Acta Paediatr Scand. 1982 Mar;71(2):275-8 PMID: 7136636
  44. Reiter's syndrome following antibiotic-associated colitis.
    Aust N Z J Med. 1982 Jun;12(3):292-3 PMID: 6956300
  45. Detection of toxigenic Clostridium difficile in stool specimens by the polymerase chain reaction.
    J Infect Dis. 1993 Feb;167(2):455-8 PMID: 8421180
  46. Treatment of Clostridium difficile colitis and diarrhea with vancomycin.
    Am J Med. 1981 Nov;71(5):815-22 PMID: 7304654
  47. Antibiotic-associated pseudomembranous colitis.
    Rev Infect Dis. 1979 May-Jun;1(3):530-9 PMID: 399365
  48. Pseudomembranous colitis: how useful is endoscopy?
    Surg Endosc. 1990;4(4):217-9 PMID: 2291163
  49. Relapse versus reinfection with Clostridium difficile.
    Epidemiol Infect. 1991 Dec;107(3):627-35 PMID: 1752311
  50. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations.
    Gastroenterology. 1981 Jul;81(1):5-9 PMID: 7239125
  51. Clostridium difficile: clinical considerations.
    Rev Infect Dis. 1990 Jan-Feb;12 Suppl 2:S243-51 PMID: 2406876
  52. Prevalence of Clostridium difficile on a mixed-function ward for the elderly.
    J Infect. 1990 Nov;21(3):287-92 PMID: 2273275
  53. Clostridial toxin in faeces of healthy infants.
    Lancet. 1978 Aug 5;2(8084):319 PMID: 79112
  54. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982.
    J Infect Dis. 1985 Mar;151(3):476-81 PMID: 3973405
  55. Role of Clostridium difficile in a case of nonantibiotic-associated pseudomembranous colitis.
    Gastroenterology. 1980 Nov;79(5 Pt 1):948-51 PMID: 7419019
  56. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.
    Gastroenterology. 1985 Nov;89(5):1038-45 PMID: 4043661
  57. Idiopathic pseudomembranous colitis successfully treated by surgical excision.
    Br J Surg. 1972 Feb;59(2):154-6 PMID: 4679679
  58. Treatment of antibiotic-associated pseudomembranous colitis.
    Rev Infect Dis. 1984 Mar-Apr;6 Suppl 1:S235-41 PMID: 6718937
  59. Is Clostridium difficile endemic in chronic-care facilities?
    Lancet. 1986 Jul 5;2(8497):11-3 PMID: 2873315
  60. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis.
    Am J Gastroenterol. 1985 Nov;80(11):867-8 PMID: 4050760
  61. Pseudomembranous colitis associated with single-dose cephalosporin prophylaxis.
    JAMA. 1989 Aug 18;262(7):902 PMID: 2754787
  62. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.
    Am J Med. 1989 Jan;86(1):15-9 PMID: 2910090
  63. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.
    Gut. 1986 Oct;27(10):1169-72 PMID: 3781329
  64. Recovery of Clostridium difficile from children.
    Scand J Infect Dis. 1981;13(1):41-5 PMID: 7244558
  65. Is Clostridium difficile pathogenic in infants?
    J Pediatr. 1982 Mar;100(3):393-5 PMID: 7062169
Article Info
Journal
Journal of general internal medicine
Abbr.
J Gen Intern Med
ISSN
0884-8734
Published
1994-09-00
Pages
528-33
Language
English
Region
United States
NLM ID
8605834
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com